{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:07:25Z","timestamp":1780920445616,"version":"3.54.1"},"reference-count":90,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T00:00:00Z","timestamp":1721865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Chronic Thromboembolic Pulmonary Hypertension (CTEPH) is a severe and complex condition that evolves from unresolved pulmonary embolism, leading to fibrotic obstruction of pulmonary arteries, pulmonary hypertension, and potential right heart failure. The cornerstone of CTEPH management lies in a multifaceted therapeutic approach tailored to individual patient profiles, reflecting the disease's heterogeneity. This review delves into the current therapeutic strategies for CTEPH, including surgical pulmonary endarterectomy (PEA), balloon pulmonary angioplasty (BPA), and targeted pharmacological treatments such as PDE5 inhibitors, endothelin receptor antagonists, sGC stimulators, and prostanoids. Lifelong anticoagulation is also highlighted as a preventive strategy against recurrent thromboembolism. Special emphasis is placed on the interdisciplinary nature of CTEPH care, necessitating collaboration among PEA surgeons, BPA interventionists, PH specialists, and thoracic radiologists to ensure comprehensive treatment planning and execution. The review underscores the importance of selecting an appropriate treatment modality based on the patient's specific disease characteristics and the evolving landscape of CTEPH treatment, aiming to improve patient outcomes through integrated care strategies.<\/jats:p>","DOI":"10.3389\/fcvm.2024.1439411","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T04:59:22Z","timestamp":1721883562000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Chronic Thromboembolic Pulmonary Hypertension: the therapeutic assessment"],"prefix":"10.3389","volume":"11","author":[{"given":"Beatrice","family":"Simeone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Maggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Schirone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Rocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmarco","family":"Sarto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Spadafora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bernardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"D\u2019Ambrosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Forte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Vecchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Sciarretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine Dario","family":"Vizza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1801913","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur Respir J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2200879","DOI":"10.1183\/13993003.00879-2022","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"61","author":"Humbert","year":"2023","journal-title":"Eur Respir J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"160121","DOI":"10.1183\/16000617.0121-2016","article-title":"An epidemiological analysis of the burden of chronic thromboembolic pulmonary hypertension in the USA, Europe and Japan","volume":"26","author":"Gall","year":"2017","journal-title":"Eur Respir Rev"},{"key":"B4","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1378\/chest.103.3.685","article-title":"Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension","volume":"103","author":"Moser","year":"1993","journal-title":"Chest"},{"key":"B5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/jth.13175","article-title":"Derivation of a clinical prediction score for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism","volume":"14","author":"Klok","year":"2016","journal-title":"J Thromb Haemost"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2002828","DOI":"10.1183\/13993003.02828-2020","article-title":"ERS statement on chronic thromboembolic pulmonary hypertension","volume":"57","author":"Delcroix","year":"2021","journal-title":"Eur Respir J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.healun.2014.07.005","article-title":"Pulmonary microvascular lesions regress in reperfused chronic thromboembolic pulmonary hypertension","volume":"34","author":"Boulate","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1183\/09031936.00169113","article-title":"Microvascular disease in chronic thromboembolic pulmonary hypertension: a role for pulmonary veins and systemic vasculature","volume":"44","author":"Dorfm\u00fcller","year":"2014","journal-title":"Eur Respir J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1161\/CIRCULATIONAHA.119.041515","article-title":"Microvascular disease in chronic thromboembolic pulmonary hypertension: hemodynamic phenotyping and histomorphometric assessment","volume":"141","author":"Gerges","year":"2020","journal-title":"Circulation"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1111\/jth.14016","article-title":"Chronic thromboembolic pulmonary hypertension from the perspective of patients with pulmonary embolism","volume":"16","author":"Klok","year":"2018","journal-title":"J Thromb Haemost"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1016\/j.jacc.2008.08.059","article-title":"Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (bosentan effects in iNopErable forms of chronic thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial","volume":"52","author":"Ja\u00efs","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa1209657","article-title":"Riociguat for the treatment of chronic thromboembolic pulmonary hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S2213-2600(17)30305-3","article-title":"Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study","volume":"5","author":"Ghofrani","year":"2017","journal-title":"Lancet Respir Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1097\/MCP.0000000000000188","article-title":"Balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension","volume":"21","author":"Ogo","year":"2015","journal-title":"Curr Opin Pulm Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/j.healun.2021.07.020","article-title":"Evaluation and management of patients with chronic thromboembolic pulmonary hypertension\u2014consensus statement from the ISHLT","volume":"40","author":"de Perrot","year":"2021","journal-title":"J Heart Lung Transplant"},{"key":"B16","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.jtcvs.2016.02.062","article-title":"Operability assessment in CTEPH: lessons from the CHEST-1 study","volume":"152","author":"Jenkins","year":"2016","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B17","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1161\/CIRCULATIONAHA.115.016522","article-title":"Long-term outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry","volume":"133","author":"Delcroix","year":"2016","journal-title":"Circulation"},{"key":"B18","first-page":"274","article-title":"Technique and outcomes of pulmonary endarterectomy surgery","volume":"14","author":"Thistlethwaite","year":"2008","journal-title":"Ann Thorac Cardiovasc Surg"},{"key":"B19","doi-asserted-by":"publisher","first-page":"S240","DOI":"10.1513\/AnnalsATS.201601-014AS","article-title":"Pulmonary endarterectomy. Patient selection, technical challenges, and outcomes","volume":"13","author":"Madani","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"B20","doi-asserted-by":"publisher","first-page":"20458940211007372","DOI":"10.1177\/20458940211007372","article-title":"Pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension: state-of-the-art 2020","volume":"11","author":"Madani","year":"2021","journal-title":"Pulm Circ"},{"key":"B21","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.healun.2015.12.029","article-title":"Pulmonary endarterectomy for distal chronic thromboembolic pulmonary hypertension","volume":"35","author":"D'Armini","year":"2016","journal-title":"J Heart Lung Transplant"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1801915","DOI":"10.1183\/13993003.01915-2018","article-title":"Chronic thromboembolic pulmonary hypertension","volume":"53","author":"Kim","year":"2019","journal-title":"Eur Respir J"},{"key":"B23","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.athoracsur.2012.04.004","article-title":"Pulmonary endarterectomy: recent changes in a single institution\u2019s experience of more than 2,700 patients","volume":"94","author":"Madani","year":"2012","journal-title":"Ann Thorac Surg"},{"key":"B24","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.jtcvs.2010.11.024","article-title":"Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry","volume":"141","author":"Mayer","year":"2011","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.healun.2022.06.013","article-title":"ISHLT consensus statement: perioperative management of patients with pulmonary hypertension and right heart failure undergoing surgery","volume":"41","author":"McGlothlin","year":"2022","journal-title":"J Heart Lung Transplant"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/S0140-6736(11)61144-6","article-title":"Circulatory arrest versus cerebral perfusion during pulmonary endarterectomy surgery (PEACOG): a randomised controlled trial","volume":"378","author":"Vuylsteke","year":"2011","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1378\/chest.81.2.151","article-title":"Longterm follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data","volume":"81","author":"Riedel","year":"1982","journal-title":"Chest"},{"key":"B28","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/S0022-5223(19)33748-1","article-title":"Experience and results with 150 pulmonary thromboendarterectomy operations over a 29-month period","volume":"106","author":"Jamieson","year":"1993","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s002689900511","article-title":"Short-term outcome and predictors of adverse events following pulmonary thromboendarterectomy","volume":"22","author":"Gilbert","year":"1998","journal-title":"World J Surg"},{"key":"B30","doi-asserted-by":"publisher","first-page":"8870","DOI":"10.1038\/s41598-020-65697-4","article-title":"Comparison of balloon pulmonary angioplasty and pulmonary vasodilators for inoperable chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis","volume":"10","author":"Kalra","year":"2020","journal-title":"Sci Rep"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1016\/j.jacc.2018.04.009","article-title":"Chronic thromboembolic pulmonary hypertension: evolving therapeutic approaches for operable and inoperable disease","volume":"71","author":"Mahmud","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e008838","DOI":"10.1161\/JAHA.118.008838","article-title":"Sequential hybrid therapy with pulmonary endarterectomy and additional balloon pulmonary angioplasty for chronic","volume":"7","author":"Yanaka","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"B33","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ijcard.2020.10.026","article-title":"The role of balloon pulmonary angioplasty and pulmonary endarterectomy: is chronic thromboembolic pulmonary hypertension still a life-threatening disease?","volume":"326","author":"Taniguchi","year":"2021","journal-title":"Int J Cardiol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"5336","DOI":"10.3390\/jcm12165336","article-title":"Emerging role of balloon pulmonary angioplasty in chronic thromboembolic pulmonary disease-insights from the 2022 ESC guidelines","volume":"12","author":"Banaszkiewicz","year":"2023","journal-title":"J Clin Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1161\/CIRCINTERVENTIONS.112.971077","article-title":"Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension","volume":"5","author":"Mizoguchi","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"B36","doi-asserted-by":"publisher","first-page":"160119","DOI":"10.1183\/16000617.0119-2016","article-title":"Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension","volume":"26","author":"Lang","year":"2017","journal-title":"Eur Respir Rev"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e001144","DOI":"10.1136\/openhrt-2019-001144","article-title":"Balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension: the UK experience","volume":"7","author":"Hoole","year":"2020","journal-title":"Open Heart"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e004029","DOI":"10.1161\/CIRCOUTCOMES.117.004029","article-title":"Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: results of a multicenter registry","volume":"10","author":"Ogawa","year":"2017","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e8137","DOI":"10.1161\/JAHA.122.027395","article-title":"Predictors of improvement in exercise tolerance after balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension","volume":"12","author":"Daigo","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"B40","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.iccl.2017.09.003","article-title":"Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension","volume":"7","author":"Mahmud","year":"2018","journal-title":"Interv Cardiol Clin"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1016\/j.jcin.2019.01.237","article-title":"Balloon pulmonary angioplasty (percutaneous transluminal pulmonary angioplasty) for chronic thromboembolic pulmonary hypertension: a Japanese perspective","volume":"12","author":"Kataoka","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"B42","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S2213-2600(22)00171-0","article-title":"Balloon pulmonary angioplasty versus riociguat in inoperable chronic thromboembolic pulmonary hypertension (MR BPA): an open-label, randomised controlled trial","volume":"10","author":"Kawakami","year":"2022","journal-title":"Lancet Respir Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/S2213-2600(22)00214-4","article-title":"Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study","volume":"10","author":"Ja\u00efs","year":"2022","journal-title":"Lancet Respir Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1253\/circj.CJ-17-1434","article-title":"Adiponectin in chronic thromboembolic pulmonary hypertension","volume":"82","author":"Isobe","year":"2018","journal-title":"Circ J"},{"key":"B45","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1253\/circj.CJ-15-1212","article-title":"Multiple beneficial effects of balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension","volume":"80","author":"Tatebe","year":"2016","journal-title":"Circ J"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1802095","DOI":"10.1183\/13993003.02095-2018","article-title":"French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension","volume":"53","author":"Brenot","year":"2019","journal-title":"Eur Respir J"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1136\/heartjnl-2015-309230","article-title":"Efficacy of cardiac rehabilitation after balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension","volume":"102","author":"Fukui","year":"2016","journal-title":"Heart"},{"key":"B48","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/jth.14649","article-title":"A multicenter study of anticoagulation in operable chronic thromboembolic pulmonary hypertension","volume":"18","author":"Bunclark","year":"2020","journal-title":"J Thromb Haemost"},{"key":"B49","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.healun.2022.02.002","article-title":"Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension","volume":"41","author":"Humbert","year":"2022","journal-title":"J Heart Lung Transplant"},{"key":"B50","doi-asserted-by":"publisher","first-page":"685","DOI":"10.7326\/M19-0291","article-title":"Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial","volume":"171","author":"Ordi-Ros","year":"2019","journal-title":"Ann Intern Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1161\/CIRCULATIONAHA.122.062779","article-title":"A randomized controlled trial comparing apixaban with the vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 study","volume":"147","author":"Reinecke","year":"2023","journal-title":"Circulation"},{"key":"B53","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1161\/CIRCULATIONAHA.123.067528","article-title":"A multicenter, single-blind, randomized, warfarin-controlled trial of edoxaban in patients with chronic thromboembolic pulmonary hypertension: KABUKI trial","volume":"149","author":"Hosokawa","year":"2024","journal-title":"Circulation"},{"key":"B54","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1586\/17476348.2015.1085805","article-title":"Developments in pulmonary arterial hypertensiontargeted therapy for chronic thromboembolic pulmonary hypertension","volume":"9","author":"Hadinnapola","year":"2015","journal-title":"Expert Rev Respir Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S2213-2600(18)30367-9","article-title":"Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial","volume":"7","author":"Sadushi-Kolici","year":"2019","journal-title":"Lancet Respir Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.healun.2006.12.014","article-title":"Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension","volume":"26","author":"Cabrol","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"B57","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1124\/jpet.108.138305","article-title":"2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug","volume":"326","author":"Kuwano","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"B58","doi-asserted-by":"publisher","first-page":"7128","DOI":"10.1021\/acs.jmedchem.5b00698","article-title":"Selexipag: an oral and selective IP prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension","volume":"58","author":"Asaki","year":"2015","journal-title":"J Med Chem"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N Engl J Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"2101694","DOI":"10.1183\/13993003.01694-2021","article-title":"Selexipag for the treatment of chronic thromboembolic pulmonary hypertension","volume":"60","author":"Ogo","year":"2022","journal-title":"Eur Respir J"},{"key":"B61","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1183\/16000617.00001015","article-title":"Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension","volume":"24","author":"Hoeper","year":"2015","journal-title":"Eur Respir Rev"},{"key":"B62","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/j.1538-7836.2007.02394.x","article-title":"Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertension","volume":"5","author":"Skoro-Sajer","year":"2007","journal-title":"J Thromb Haemost"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1253\/circj.CJ-20-0438","article-title":"Selexipag for chronic thromboembolic pulmonary hypertension in Japanese patients\u2014a double-blind, randomized, placebo-controlled, multicenter phase II study","volume":"84","author":"Tanabe","year":"2020","journal-title":"Circ J"},{"key":"B64","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/CRD.0b013e3181cd2c9e","article-title":"Pulmonary arterial hypertension: pathobiology, diagnosis, treatment, and emerging therapies","volume":"18","author":"Rosenblum","year":"2010","journal-title":"Cardiol Rev"},{"key":"B65","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s10557-015-6605-6","article-title":"Pathways and drugs in pulmonary arterial hypertension\u2014focus on the role of endothelin receptor antagonists","volume":"29","author":"Madonna","year":"2015","journal-title":"Cardiovasc Drugs Ther"},{"key":"B66","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1183\/16000617.0067-2015","article-title":"Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension","volume":"24","author":"Lang","year":"2015","journal-title":"Eur Respir Rev"},{"key":"B67","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jtcvs.2009.03.053","article-title":"Bosentan as a bridge to pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension","volume":"139","author":"Reesink","year":"2010","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B68","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","article-title":"2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European respiratory society (ERS): endorsed by: association for European paediatric and congenital cardiology (AEPC), international society for heart and lung transplantation (ISHLT)","volume":"37","author":"Gali\u00e8","year":"2016","journal-title":"Eur Heart J"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Gali\u00e8","year":"2005","journal-title":"N Engl J Med"},{"key":"B70","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1183\/09031936.00039007","article-title":"Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension","volume":"30","author":"Reichenberger","year":"2007","journal-title":"Eur Respir J"},{"key":"B71","doi-asserted-by":"publisher","first-page":"00850","DOI":"10.1183\/23120541.00850-2020","article-title":"Current strategies for managing chronic thromboembolic pulmonary hypertension: results of the worldwide prospective CTEPH registry","volume":"7","author":"Guth","year":"2021","journal-title":"ERJ Open Res"},{"key":"B72","doi-asserted-by":"publisher","first-page":"160107","DOI":"10.1183\/16000617.0107-2016","article-title":"Medical management of chronic thromboembolic pulmonary hypertension","volume":"26","author":"Pepke-Zaba","year":"2017","journal-title":"Eur Respir Rev"},{"key":"B73","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1183\/09031936.00039808","article-title":"First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension","volume":"33","author":"Grimminger","year":"2009","journal-title":"Eur Respir J"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1164\/rccm.202012-4317SO","article-title":"Pulmonary arterial hypertension: diagnosis, treatment, and novel advances","volume":"203","author":"Maron","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"B75","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1183\/09031936.00090614","article-title":"Riociguat for the treatment of pulmonary arterial hypertension: a longterm extension study (PATENT-2)","volume":"45","author":"Rubin","year":"2015","journal-title":"Eur Respir J"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1183\/09031936.00105914","article-title":"PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension","volume":"45","author":"Gali\u00e8","year":"2015","journal-title":"Eur Respir J"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1183\/09031936.00087114","article-title":"Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2)","volume":"45","author":"Simonneau","year":"2015","journal-title":"Eur Respir J"},{"key":"B79","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ijcard.2015.05.105","article-title":"Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension","volume":"195","author":"Marra","year":"2015","journal-title":"Int J Cardiol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1161\/CIRCULATIONAHA.109.865881","article-title":"Pulmonary hypertensive medical therapy in chronic thromboembolic pulmonary hypertension before pulmonary thromboendarterectomy","volume":"120","author":"Jensen","year":"2009","journal-title":"Circulation"},{"key":"B81","doi-asserted-by":"publisher","first-page":"D42","DOI":"10.1016\/j.jacc.2013.10.032","article-title":"Definitions and diagnosis of pulmonary hypertension","volume":"62","author":"Hoeper","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1161\/CIRCULATIONAHA.115.019470","article-title":"Dynamic risk stratification of patient long-term outcome after pulmonary endarterectomy: results from the United Kingdom national cohort","volume":"133","author":"Cannon","year":"2016","journal-title":"Circulation"},{"key":"B83","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1253\/circj.cj-11-1217","article-title":"Percutaneous transluminal pulmonary angioplasty markedly improves pulmonary hemodynamics and long-term prognosis in patients with chronic thromboembolic pulmonary hypertension","volume":"76","author":"Sugimura","year":"2012","journal-title":"Circ J"},{"key":"B84","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.healun.2014.09.016","article-title":"Prognostic implications of serial risk score assessments in patients with pulmonary arterial hypertension: a registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL) analysis","volume":"34","author":"Benza","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"B85","doi-asserted-by":"publisher","first-page":"106783","DOI":"10.1016\/j.rmed.2022.106783","article-title":"Application of the REVEAL risk score calculator 2.0 in the CHEST study","volume":"195","author":"Benza","year":"2022","journal-title":"Respir Med"},{"key":"B86","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ijcard.2021.03.034","article-title":"Application of the REVEAL risk score calculator 2.0 in the PATENT study","volume":"332","author":"Benza","year":"2021","journal-title":"Int J Cardiol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1161\/CIRCULATIONAHA.110.015008","article-title":"Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry","volume":"124","author":"Pepke-Zaba","year":"2011","journal-title":"Circulation"},{"key":"B88","doi-asserted-by":"publisher","first-page":"00564","DOI":"10.1183\/23120541.00564-2021","article-title":"Noninvasive follow-up strategy after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension","volume":"8","author":"Ruigrok","year":"2022","journal-title":"ERJ Open Res"},{"key":"B89","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1093\/ehjci\/jeaa243","article-title":"The echocardiographic ratio tricuspid annular plane systolic excursion\/pulmonary arterial systolic pressure predicts short-term adverse outcomes in acute pulmonary embolism","volume":"22","author":"Lyhne","year":"2021","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"B90","doi-asserted-by":"publisher","first-page":"20406223221102803","DOI":"10.1177\/20406223221102803","article-title":"Prognostic implication of noninvasive right ventricle-to-pulmonary artery coupling in chronic thromboembolic pulmonary hypertension","volume":"13","author":"Duan","year":"2022","journal-title":"Ther Adv Chronic Dis"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1439411\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T14:02:30Z","timestamp":1723039350000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1439411\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,25]]},"references-count":90,"alternative-id":["10.3389\/fcvm.2024.1439411"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2024.1439411","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,25]]},"article-number":"1439411"}}